Web9 aug. 2024 · About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’s lead molecule is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in a fundamental CNS signaling network. Web1 apr. 2024 · – Ironwood capitalizing on GI leadership and expertise in an effort to bring innovative therapies to patients – – Strategy centered on accelerating LINZESS ® (linaclotide) growth and advancing late-stage programs IW-3718 and MD-7246 – – Business poised to drive revenue growth and begin generating profits – Ironwood …
BARRY WYTHOFF, supervisor supervisor, Research Informatics, cyclerion
WebLiked by Meghan Bratton. ... Director, Head of Clinical Operations at Cyclerion Boston, MA. Meghan Bratton backroom at Target Shawnee, KS. 2 others named Meghan … WebFind out the professional email of SARAH J., Científico Senior, cyclerion. GetEmail.io : get anyone's email address in seconds. GetEmail.io. Back to homepage clevedon branch line
Cyclerion Therapeutics Announces Topline Phase 2 Results for …
Web4 jun. 2024 · Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties. Praliciguat out-licensing further enables Cyclerion’s strategic focus on CNS, including first-in-class CNS-penetrant sGC stimulators CY6463 and CY3018. WebExperience Senior Director, Clinical Operations Cardurion Pharmaceuticals Jan 2024 - Present4 months Burlington, Massachusetts, United States … WebFind out the professional email of KARTHIK IYER , Principal Investigator, Medicinal Chemistry, cyclerion. GetEmail.io : get anyone's email address in seconds. GetEmail.io. Back to homepage clevedon bridge bath closure